Search

everythinglearnresearchcommunity

for

Search:↓

A hair loss regimen involving Dutasteride, Oral Minoxidil, Mesotherapy, Topical Minoxidil/Finasteride, RU58841, Alfatridiol, Microneedling, LLLT, Keto shampoo, Vitamin K/D/Fish oil/Borage Oil/MSM, Oral Castor oil and Niacin. It also mentions products that have been dropped from the regimen due to not being worth the hassle or messing with libido.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

The conversation discusses a hair regrowth protocol involving Dutasteride, Pyrilutamide, Stemoxydine, Minoxidil, Tretinoin, Oral Castor Oil, and L-Carnitine L-Tartrate. Some users are skeptical, particularly about the effectiveness and side effects of oral castor oil.

The user experienced side effects from low-dose topical finasteride and is considering using clascoterone (CB-03-01) despite concerns about its risks and cost. They seek advice on its effectiveness and potential side effects compared to other treatments like alfatradiol and fluridil.

The user has been using a combination of oral and topical minoxidil, topical finasteride, RU58841, Nizoral, and microneedling for hair loss treatment. They report improvement in hair thickness except for the crown area, which has not changed.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

The user is addressing hair loss with scalp botox, scalp massage, nizoral shampoo, various vitamins and supplements, and natural nitric oxide boosters like citrulline malate and beetroot powder. They are also considering a mouthpiece to reduce snoring and improve sleep.

The regimen for hair loss includes topical finasteride, clascoterone, tretinoin, minoxidil, oral saw palmetto, beta-sitosterol, vitamin D, microneedling, and anti-fungal shampoo. Expected benefits are increased hair growth and density, with considerations for potential skin irritation and interactions between treatments.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.

The user is using a hair loss treatment regimen that includes double the recommended dose of Minoxidil foam once nightly, a mix of RU58841 and stemoxydine after the Minoxidil dries, ketoconazole every other day, and weekly microneedling with alternating depths. They are also considering starting finasteride soon.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation covers aggressive hair regrowth treatments like Dutasteride, Minoxidil (oral and topical), RU58841, microneedling, and ketoconazole shampoo. It also mentions PRP, laser therapy, GHK-Cu injections, and hormone therapy for maximum regrowth.

The user is taking 0.5mg finasteride and 0.5mg Loniten orally daily, using Eucapil twice weekly, and Minoxidil foam once daily for hair loss. They believe Eucapil effectively stops hair loss despite side effects like breast growth.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The conversation discusses a hair regrowth treatment containing Minoxidil, Procapil, Sandalore, and caffeine. The focus is on evaluating the effectiveness of this product available on eBay.

The conversation is about hair loss treatment using finasteride, ketoconazole, and sulfur soap, with consideration of starting dermastamp. The user prefers not to use minoxidil.

A 3-month update on the progress using finasteride and ketoconazole as treatments for hair loss, with the routine and dosage discussed.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

A 29-year-old reports positive hair recovery after 7 months using liposomal topical finasteride and minoxidil, low-level light therapy, and vitamins, following a 3600 graft DHI procedure. They experienced no side effects from the topical treatment, unlike with oral finasteride.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

The regimen includes using a diluted 5.5% Minoxidil / 0.025% Finasteride solution daily, microneedling weekly, and ketoconazole shampoo twice a week to minimize systemic exposure while maximizing scalp DHT reduction. The goal is to achieve hair regrowth with minimal side effects.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

OP is experiencing dandruff and is considering switching from climbazole to ketoconazole, with suggestions to use Nizoral and a routine involving ketoconazole, coconut oil, and lemon. OP is also using minoxidil and finasteride for hair loss, and there are discussions about various shampoos and treatments for dandruff.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

The user is considering simplifying their post-hair transplant regimen, which currently includes oral finasteride, topical minoxidil, and has topical finasteride and dutasteride available but unused. They seek advice on whether to maintain or adjust their treatment plan to achieve the minimum effective treatment.

The user is considering whether to add RU58841 or Nizoral shampoo to their current hair loss treatment of finasteride and minoxidil, noting budget constraints and concerns about hair dryness. They are unsure if RU58841 is worth adding or if they should use both treatments to see the effects.